David J Matye1,2, Yuan Li2, Cheng Chen1, Xiaojuan Chao2, Huaiwen Wang3, Hongmin Ni2, Wen-Xing Ding2, Tiangang Li1. 1. Harold Hamm Diabetes Center, Department of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 2. Department of Pharmacology, Toxicology, Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA. 3. Laboratory For Molecular Biology and Cytometry Research, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Abstract
BACKGROUND: Recent studies have shown that human and experimental alcohol-related liver disease (ALD) is robustly associated with dysregulation of bile acid homeostasis, which may in turn modulate disease severity. Pharmacological agents targeting bile acid metabolism and signaling may be potential therapeutics for ALD. METHODS: The potential beneficial effects of a gut-restricted apical sodium-dependent bile acid transporter (ASBT) inhibitor were studied in a chronic-plus-binge ALD mouse model. RESULTS: Blocking intestinal bile acid reabsorption by the gut-restricted ASBT inhibitor GSK2330672 attenuated hepatic steatosis and liver injury in a chronic-plus-binge ALD mouse model. Alcohol feeding is associated with intestinal bile acid accumulation but paradoxically impaired ileal farnesoid × receptor (FXR) function, and repressed hepatic cholesterol 7α-hydrolase (CYP7A1) expression despite decreased hepatic small heterodimer partner (SHP) and ileal fibroblast growth factor 15 (FGF15) expression. ASBT inhibitor treatment decreased intestinal bile acid accumulation and increased hepatic CYP7A1 expression, but further decreased ileal FXR activity. Alcohol feeding induces serum bile acid concentration that strongly correlates with a liver injury marker. However, alcohol-induced serum bile acid elevation is not due to intrahepatic bile acid accumulation but is strongly and positively associated with hepatic multidrug resistance-associated protein 3 (MRP4) and MRP4 induction but poorly associated with sodium-taurocholate cotransporting peptide (NTCP) expression. ASBT inhibitor treatment decreases serum bile acid concentration without affecting hepatocyte basolateral bile acid uptake and efflux transporters. CONCLUSION: ASBT inhibitor treatment corrects alcohol-induced bile acid dysregulation and attenuates liver injury in experimental ALD.
BACKGROUND: Recent studies have shown that human and experimental alcohol-related liver disease (ALD) is robustly associated with dysregulation of bile acid homeostasis, which may in turn modulate disease severity. Pharmacological agents targeting bile acid metabolism and signaling may be potential therapeutics for ALD. METHODS: The potential beneficial effects of a gut-restricted apical sodium-dependent bile acid transporter (ASBT) inhibitor were studied in a chronic-plus-binge ALD mouse model. RESULTS: Blocking intestinal bile acid reabsorption by the gut-restricted ASBT inhibitor GSK2330672 attenuated hepatic steatosis and liver injury in a chronic-plus-binge ALD mouse model. Alcohol feeding is associated with intestinal bile acid accumulation but paradoxically impaired ileal farnesoid × receptor (FXR) function, and repressed hepatic cholesterol 7α-hydrolase (CYP7A1) expression despite decreased hepatic small heterodimer partner (SHP) and ileal fibroblast growth factor 15 (FGF15) expression. ASBT inhibitor treatment decreased intestinal bile acid accumulation and increased hepatic CYP7A1 expression, but further decreased ileal FXR activity. Alcohol feeding induces serum bile acid concentration that strongly correlates with a liver injury marker. However, alcohol-induced serum bile acid elevation is not due to intrahepatic bile acid accumulation but is strongly and positively associated with hepatic multidrug resistance-associated protein 3 (MRP4) and MRP4 induction but poorly associated with sodium-taurocholate cotransporting peptide (NTCP) expression. ASBT inhibitor treatment decreases serum bile acid concentration without affecting hepatocyte basolateral bile acid uptake and efflux transporters. CONCLUSION: ASBT inhibitor treatment corrects alcohol-induced bile acid dysregulation and attenuates liver injury in experimental ALD.
Authors: Alexander G Miethke; Wujuan Zhang; Julia Simmons; Amy E Taylor; Tiffany Shi; Shiva Kumar Shanmukhappa; Rebekah Karns; Shana White; Anil G Jegga; Celine S Lages; Stephenson Nkinin; Bradley T Keller; Kenneth D R Setchell Journal: Hepatology Date: 2015-08-21 Impact factor: 17.425
Authors: Takeshi Inagaki; Mihwa Choi; Antonio Moschetta; Li Peng; Carolyn L Cummins; Jeffrey G McDonald; Guizhen Luo; Stacey A Jones; Bryan Goodwin; James A Richardson; Robert D Gerard; Joyce J Repa; David J Mangelsdorf; Steven A Kliewer Journal: Cell Metab Date: 2005-10 Impact factor: 27.287
Authors: Anuradha Rao; Jamie Haywood; Ann L Craddock; Martin G Belinsky; Gary D Kruh; Paul A Dawson Journal: Proc Natl Acad Sci U S A Date: 2008-02-21 Impact factor: 11.205
Authors: Takeshi Inagaki; Antonio Moschetta; Youn-Kyoung Lee; Li Peng; Guixiang Zhao; Michael Downes; Ruth T Yu; John M Shelton; James A Richardson; Joyce J Repa; David J Mangelsdorf; Steven A Kliewer Journal: Proc Natl Acad Sci U S A Date: 2006-02-10 Impact factor: 11.205
Authors: Anna Baghdasaryan; Claudia D Fuchs; Christoph H Österreicher; Ursula J Lemberger; Emina Halilbasic; Ingrid Påhlman; Hans Graffner; Elisabeth Krones; Peter Fickert; Annika Wahlström; Marcus Ståhlman; Gustav Paumgartner; Hanns-Ulrich Marschall; Michael Trauner Journal: J Hepatol Date: 2015-10-31 Impact factor: 25.083
Authors: Mingxing Huang; Bo Kong; Min Zhang; Daniel Rizzolo; Laura E Armstrong; Justin D Schumacher; Monica D Chow; Yi-Horng Lee; Laurie B Joseph; Mary Stofan; Lanjing Zhang; Grace L Guo Journal: Lab Invest Date: 2020-05-13 Impact factor: 5.662